Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kaiqi, Li, Yan, Qiu, Shaowei, Zhou, Chunlin, Wei, Shuning, Lin, Dong, Zhang, Guangji, Wei, Hui, Wang, Ying, Liu, Bingcheng, Gong, Xiaoyuan, Fang, Qiuyun, Song, Yang, Wang, Huijun, Li, Chengwen, Li, Qinghua, Wu, Lihua, Gong, Benfa, Liu, Yuntao, Wang, Jianxiang, Mi, Yingchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447663/
https://www.ncbi.nlm.nih.gov/pubmed/34530914
http://dx.doi.org/10.1186/s40164-021-00239-w
Descripción
Sumario:Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-021-00239-w.

Ejemplares similares